ACT001 in combination with SHP099 further reduced tumor burden (Figures 7B-7E), p-AKT, the expression of AEBP1, Ki-67, hNestin (Figure 7G), and extended survival to a greater extent than ACT001 treatment alone (Figure 7F), suggesting that the combination of ACT001 and SHP099 synergizes to extend the survival in our GSC xenograft model (Figure 7H). This evidence concerns the gene AKT1 and neoplasm.